Interleukin-6 modifies Lipoprotein(a) and oxidized phospholipids associated cardiovascular disease risk in a secondary prevention cohort
In patients with CCS, Lp(a), OxPL-apo(a) and OxPL-apoB associated cardiovascular risk was only pertinent in those with elevated IL-6 but not hsCRP levels.
Authors
- Niekbachsh Mohammadnia (ORCID: https://orcid.org/0000-0002-5968-3817)
- Jan H. Cornel (ORCID: https://orcid.org/0000-0002-1006-2112)
- Aernoud T.L. Fiolet
- Amber van Broekhoven (ORCID: https://orcid.org/0000-0002-4204-7750)
- Arend Mosterd (ORCID: https://orcid.org/0000-0002-6906-2643)
- Willem A. Bax (ORCID: https://orcid.org/0000-0002-2177-1475)
- John W. Eikelboom (ORCID: https://orcid.org/0000-0003-4126-1285)
- Calvin Yeang (ORCID: https://orcid.org/0000-0002-5927-9291)
- Sotirios Tsimikas (ORCID: https://orcid.org/0000-0001-9834-9494)
- Jan G.P. Tijssen (ORCID: https://orcid.org/0000-0003-1707-2628)
- Saloua El Messaoudi (ORCID: https://orcid.org/0009-0006-0804-2071)
- Peter Thompson
- Dominique P V de Kleijn
Institutions
- Radboud University Nijmegen (NL)
- Sir Charles Gairdner Hospital (AU)
- Radboud University Medical Center (NL)
- University Medical Center Utrecht (NL)
- University of California San Diego (US)
- Northwest Hospital (US)
- Netherlands Heart Institute (NL)
- Amsterdam University Medical Centers (NL)
- Meander Medisch Centrum (NL)
- McMaster University (CA)
Publication Details
- Journal
- Atherosclerosis
- Published
- 2025-04-26
- DOI
- https://doi.org/10.1016/j.atherosclerosis.2025.119211
- Citations
- 9
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 18.06
Funders
- Foundation for the National Institutes of Health
- National Institutes of Health